Next Article in Journal
On Neutrosophic Triplet Groups: Basic Properties, NT-Subgroups, and Some Notes
Previous Article in Journal
Space-Time Second-Quantization Effects and the Quantum Origin of Cosmological Constant in Covariant Quantum Gravity
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessFeature PaperArticle
Symmetry 2018, 10(7), 288;

Stability Study of Etoricoxib a Selective Cyclooxygenase-2 Inhibitor by a New Single and Rapid Reversed Phase HPLC Method

Department of Pharmaceutical Sciences, Faculty of Pharmacy, The University of Jordan, Amman 11942, Jordan
Department of Biomedical Engineering, Faculty of Applied Medical Sciences, German Jordanian University, Amman 11180, Jordan
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The University of Jordan, Amman 11942, Jordan
Authors to whom correspondence should be addressed.
Received: 16 June 2018 / Revised: 12 July 2018 / Accepted: 12 July 2018 / Published: 17 July 2018
Full-Text   |   PDF [711 KB, uploaded 17 July 2018]   |  


Cyclooxygenase-2 (COX-2) is an enzyme responsible for inflammation and pain. Etoricoxib is the most recent selective (COX-2) inhibitor that has a higher COX-2 selectivity than the other COX-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs), which significantly improves its gastric safety profile. The current therapeutic indications of etoricoxib includes the treatment of several painful conditions, such as osteoarthritis, acute gout, ankylosing spondylitis, and rheumatoid arthritis. To the best of found knowledge, no decent method has been reported that can be used for the routine determination of etoricoxib and additives in pharmaceutical suspensions by a single, rapid and cost-effective run of HPLC, using an UV-Vis detector. Earlier reported methods, such as liquid chromatography-mass spectrometry (LC-MS), high performance thin layer chromatography (HPTLC), capillary zone electrophoresis, and ultra performance liquid chromatography (UPLC), are all tedious and time consuming. A reversed phase high performance liquid chromatography (RP-HPLC) was used as a first reported single run method to achieve developed and validated simultaneous determination for sodium saccharin, vanillin, methyl paraben, etoricoxib, and butyl paraben, in prepared oral suspensions of etoricoxib. Reversed phase column of octadecylsilane (ODS) C18 with isocratic mobile phase containing methanol, and phosphate buffer of pH 6 in a ratio of 70:30 (v/v). Celecoxib is used as an internal standard at a detection wavelength of 215 nm. This method separates the analytes in a total running time less than 13 min. Linearity is obtained in the calibration curve for all analytes with a R2 value of > 0.999. Furthermore, beta-cyclodextrin (β-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) were added, either alone or combined, to prevent the crystal formation, and any unpleasant taste of etoricoxib in oral formulations. After testing both HP-β-CD and β-CD at 3% w/w for each, the results showed that HP-β-CD is more efficient in preventing the crystal formation of etoricoxib in suspensions at room temperature than β-CD is. View Full-Text
Keywords: crystal growth; etoricoxib; excipients; HPLC; validation crystal growth; etoricoxib; excipients; HPLC; validation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Alzweiri, M.; Sallam, M.; Al-Zyoud, W.; Aiedeh, K. Stability Study of Etoricoxib a Selective Cyclooxygenase-2 Inhibitor by a New Single and Rapid Reversed Phase HPLC Method. Symmetry 2018, 10, 288.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Symmetry EISSN 2073-8994 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top